Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method | Zendy

Jean-Claude Soufir | Zendy; G Meduri | Zendy; Ahmed Ziyyat | Zendy

Open Access

Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method

Author(s) -

Jean-Claude Soufir,

G Meduri,

Ahmed Ziyyat

Publication year - 2011

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/der138

Subject(s) - medroxyprogesterone acetate , testosterone (patch) , luteinizing hormone , spermatogenesis , male contraceptive , medicine , population , endocrinology , hormone , pregnancy rate , medroxyprogesterone , physiology , gynecology , andrology , pregnancy , biology , family planning , environmental health , research methodology , genetics

We previously demonstrated in a small pilot study that oral medroxyprogesterone acetate and percutaneous testosterone (OMP/PT) induce reversible spermatogenesis suppression. The aims of this study were to determine the rate of spermatogenetic inhibition and recovery and to obtain preliminary data on efficacy for a larger population under OMP/PT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research